Lineage Cell Therapeutics Statistics

Total Valuation

TLV:LCTX has a market cap or net worth of ILS 346.29 million. The enterprise value is 174.13 million.

Market Cap	346.29M
Enterprise Value	174.13M

Important Dates

The last earnings date was Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+15.94%
Shares Change (QoQ)	+27.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	177.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.49
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.57
EV / Sales	4.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.02

Financial Position

The company has a current ratio of 3.65, with a Debt / Equity ratio of 0.03.

Current Ratio	3.65
Quick Ratio	3.47
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -26.73% and return on invested capital (ROIC) is -18.58%.

Return on Equity (ROE)	-26.73%
Return on Assets (ROA)	-12.53%
Return on Invested Capital (ROIC)	-18.58%
Return on Capital Employed (ROCE)	-21.64%
Revenue Per Employee	467,543
Profits Per Employee	-915,940
Employee Count	77
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.66% in the last 52 weeks. The beta is 1.28, so TLV:LCTX's price volatility has been higher than the market average.

Beta (5Y)	1.28
52-Week Price Change	-69.66%
50-Day Moving Average	215.68
200-Day Moving Average	271.08
Relative Strength Index (RSI)	30.84
Average Volume (20 Days)	27,757

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	12.38

Income Statement

In the last 12 months, TLV:LCTX had revenue of ILS 34.60 million and -67.78 million in losses. Loss per share was -0.34.

Revenue	34.60M
Gross Profit	-12.05M
Operating Income	-78.23M
Pretax Income	-67.68M
Net Income	-67.78M
EBITDA	-76.01M
EBIT	-78.23M
Loss Per Share	-0.34

Full Income Statement

Balance Sheet

The company has 174.12 million in cash and 9.16 million in debt, giving a net cash position of 164.96 million.

Cash & Cash Equivalents	174.12M
Total Debt	9.16M
Net Cash	164.96M
Net Cash Per Share	n/a
Equity (Book Value)	280.50M
Book Value Per Share	1.30
Working Capital	134.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -84.11 million and capital expenditures -2.06 million, giving a free cash flow of -86.17 million.

Operating Cash Flow	-84.11M
Capital Expenditures	-2.06M
Free Cash Flow	-86.17M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -34.81%, with operating and profit margins of -226.11% and -195.90%.

Gross Margin	-34.81%
Operating Margin	-226.11%
Pretax Margin	-195.62%
Profit Margin	-195.90%
EBITDA Margin	-219.70%
EBIT Margin	-226.11%
FCF Margin	n/a

Dividends & Yields

TLV:LCTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.94%
Shareholder Yield	-15.94%
Earnings Yield	-19.57%
FCF Yield	-24.88%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:LCTX has an Altman Z-Score of -2.09. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.09
Piotroski F-Score	n/a